Oncopeptides
Biotech firm developing targeted therapies for hematological cancers.
ONCO | ST
Overview
Corporate Details
- ISIN(s):
- SE0009414576 (+4 more)
- LEI:
- 549300J9WWQ5CBYQ1M77
- Country:
- Sweden
- Address:
- Luntmakargatan 46, 111 37 Stockholm
- Website:
- https://www.oncopeptides.com/en
- Sector:
- Manufacturing
Description
Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-09 08:40 |
Oncopeptides utser Henrik Bergentoft till finanschef
|
Swedish | PDF • 70.2 KB | ||
| 2023-08-07 15:07 |
Sofia Heigis appointed CEO of Oncopeptides AB (publ)
|
English | PDF • 71.5 KB | ||
| 2023-08-07 15:07 |
Sofia Heigis utsedd till VD för Oncopeptides AB (publ)
|
Swedish | PDF • 72.3 KB | ||
| 2023-07-31 08:00 |
Number of shares and votes in Oncopeptides
|
English | PDF • 69.1 KB | ||
| 2023-07-31 08:00 |
Antal aktier och röster i Oncopeptides
|
Swedish | PDF • 68.4 KB | ||
| 2023-06-28 15:39 |
Issue and re-purchase of class C shares for shareholder program
|
English | PDF • 69.1 KB | ||
| 2023-06-28 15:39 |
Emission och återköp av C-aktier för aktieägarprogram
|
Swedish | PDF • 70.5 KB | ||
| 2023-06-14 08:00 |
Holger Lembrér will leave his role as Chief Financial Officer at Oncopeptides
|
English | PDF • 69.9 KB | ||
| 2023-06-14 08:00 |
Holger Lembrér lämnar rollen som Chief Financial Officer på Oncopeptides
|
Swedish | PDF • 69.8 KB | ||
| 2023-05-25 16:45 |
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
|
English | PDF • 68.4 KB | ||
| 2023-05-25 16:45 |
Kommuniké från årsstämma i Oncopeptides AB (publ)
|
Swedish | PDF • 68.9 KB | ||
| 2023-05-04 08:00 | Swedish | PDF • 615.6 KB | |||
| 2023-05-04 08:00 | English | PDF • 658.5 KB | |||
| 2023-05-03 09:00 |
Oncopeptides issues warrants to utilize the first loan tranche from EIB
|
English | PDF • 65.2 KB | ||
| 2023-05-03 09:00 |
Oncopeptides utfärdar teckningsoptioner för att nyttja första lånetranchen från…
|
Swedish | PDF • 65.8 KB |
Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oncopeptides
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oncopeptides via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,350.00 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,312.50 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 438 | 2,225.04 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 60 | 303.60 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 2 | 10.02 SEK |
| 2023-09-08 | David Augustsson | Other | Buy | 2,296 | 17,706.75 SEK |
| 2023-08-10 | David Augustsson | Other | Buy | 1,704 | 14,995.20 SEK |
| 2023-05-04 | Nicolaas Bakker | Other | Buy | 5,000 | 42,380.00 SEK |
| 2022-10-10 | Nicolaas Bakker | Other | Buy | 15,000 | 164,400.00 SEK |
| 2022-08-30 | Per Wold-Olsen | Other | Buy | 2,050 | 55,350.00 SEK |
Peer Companies
